1 to 9 of 16 results

AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA


Anglo-Swedish drug major AstraZeneca (LSE: AZN) yesterday (May 21) presented the results of two pivotal…

Anti-viralsAstraZenecaBiotechnologyEuropeGastro-intestinalsGilead SciencesnaloxegolNektar TherapeuticsPharmaceuticalRegulationResearchsofosbuvir

Clinical briefs from Novartis, Gilead and AstraZeneca


Swiss drug major Novartis (NOVN: VX) has released new two-year results from the largest Phase III study…

ACZ885Anti-Arthritics/RheumaticsAnti-viralsAstraZenecaBiotechnologyCerticanGilead SciencesnaloxegolNeurologicalNovartisPharmaceuticalResearchsofosbuvir

Biotech has positive year, despite weak 2007 fourth quarter, says Burrill


"The biotech industry finished the year in good shape with the Burrill Biotech Select Index, a price-weighted…

AmgenAranespAstraZenecaDarbepoetin AlfaEpoetin AlfaEpogenGenentechGilead SciencesGiliad ScienceslenalidomideProcritRevlimidRoche

1 to 9 of 16 results

Back to top